SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Day One Biopharmaceuticals, Inc. (DAWN) has a negative trailing P/E of -20.7, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 87.5 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -4.83%, forward earnings yield 1.14%. PEG 0.50 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (83/100, Pass) — PEG ≤ 1.0 — Peter Lynch undervalued (0.50); analyst target implies upside (+10.7%).
- Forward P/E 87.5 — analysts expect a return to profitability with estimated EPS of $0.25 for FY2028.
- PEG Ratio 0.50 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield -4.83% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 1.14% as earnings recover.
- Analyst consensus target $23.75 (+10.7% upside) — modest upside expected.
Overall SharesGrow Score: 51/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
83/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — DAWN
Valuation Multiples
P/E (TTM)-20.7
Forward P/E87.5
PEG Ratio0.50
Forward PEG0.50
P/B Ratio5.03
P/S Ratio14.03
EV/EBITDA-19.1
Per Share Data
EPS (TTM)$-1.04
Forward EPS (Est.)$0.25
Book Value / Share$4.27
Revenue / Share$1.53
FCF / Share$-1.04
Yields & Fair Value
Earnings Yield-4.83%
Forward Earnings Yield1.14%
Dividend Yield0.00%
Analyst Target$23.75 (+10.7%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2019 |
-115.2 |
0.00 |
-136.36 |
0.00 |
- |
| 2020 |
-35.9 |
-0.21 |
38.54 |
0.00 |
- |
| 2021 |
-14.8 |
-0.20 |
3.71 |
0.00 |
- |
| 2022 |
-9.9 |
-0.13 |
4.24 |
0.00 |
- |
| 2023 |
-6.2 |
-0.36 |
3.36 |
0.00 |
- |
| 2024 |
-12.4 |
0.22 |
2.36 |
9.04 |
- |
| 2025 |
-9.0 |
-4.58 |
2.18 |
6.09 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2019 |
$-0.24 |
$0.00 |
$-14.71M |
- |
| 2020 |
$-0.65 |
$0.00 |
$-40.51M |
- |
| 2021 |
$-1.14 |
$0.00 |
$-70.44M |
- |
| 2022 |
$-2.02 |
$0.00 |
$-132.18M |
- |
| 2023 |
$-2.37 |
$0.00 |
$-188.92M |
- |
| 2024 |
$-1.02 |
$131.16M |
$-95.5M |
-72.8% |
| 2025 |
$-1.04 |
$158.18M |
$-107.32M |
-67.8% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$-0.78 |
$-1.83 – $-0.15 |
$240.45M |
$230.85M – $251.43M |
7 |
| 2027 |
$-0.18 |
$-22.17 – $11.64 |
$308.07M |
$298.86M – $319.26M |
6 |
| 2028 |
$0.25 |
$-0.05 – $0.99 |
$398.7M |
$394.77M – $402.64M |
6 |
| 2029 |
$1.25 |
$1.15 – $1.35 |
$532.92M |
$502.8M – $567.75M |
4 |
| 2030 |
$1.85 |
$1.71 – $2.00 |
$637.33M |
$601.31M – $678.98M |
2 |
